Ursa Medicines

Ursa Medicines was a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases, specifically targeting alpha-synuclein. Founded as a stealth company by Atlas Venture, it centered its efforts on a monoclonal antibody designed to inhibit the aggregation of alpha-synuclein, a key protein involved in the pathogenesis of Parkinson's disease and Multiple System Atrophy (MSA). In 2019, the company was acquired by Lundbeck to bolster its neurology pipeline and expand its presence in biologics. The lead asset, now known as Lu AF82422, has since progressed into Phase 2 clinical trials for the treatment of MSA. The acquisition included an upfront payment of $70 million with additional potential milestone payments. The company's approach aimed to provide a disease-modifying treatment for patients with synucleinopathies who currently have limited therapeutic options.